

# Ryanodine receptor 2 (RYR2) (dephoSer2808) pAb serum

# Materials Safety Datasheet

#### 1: Product and Company Identification

Catalogue No.: A010-35AP

Product name: Ryanodine receptor 2 (RYR2) (dephoSer2808) pAb serum

Company name: Badrilla Ltd

Emergency contact: Badrilla Ltd +44 7801 730 618
Information: Badrilla Ltd www.badrilla.com
Chemical Family: Monoclonal and polyclonal antibody

# 2: Composition & information on ingredients

Hazardous components chemical name

CAS No. NA
Percentage 100%
OSHA PEL no data
ACGIH TLV no data
Other limits no data

#### 3: Hazard Identification

Emergency overview: no data available

Route(s) of entry: Inhalation: Yes skin: Yes Eyes: Yes Ingestion: Yes other: Injection

Potential Health Effects (Acute and Chronic) Material may be irritating to the mucous membranes and upper respiratory tract. May

be harmful by inhalation, ingestion, or skin absorption. May cause eye, skin or respiritory tract irritation. The toxicological properties of this compound have not

been fully evaluated. No data available.

# 4: Emergency and First Aid Procedures

Signs and symptoms of Exposure:

If inhaled, remove to fresh air. If not breathing, give artificial respiration or give oxygen by trained personnel. Get immediate medical attention. If swallowed, wash out mouth with water provided person is conscious. Never give anything by mouth to an unconscious person. Get medical attention. Do not induce vomiting unless directed to do so by medical personnel. In case of contact with eyes, hold eyelids apart and flush with plenty of water. After initial flushings, remove any contact lenses and continue flushing for at least 20 minutes. Have eyes examined and tested by medical personnel. In case of skin contact, immediately wash skin with soap and plenty of water. Remove contaminated clothing. Get medical attention if symptoms occur. Wash clothing before reuse.

## 5: Fire fighting measures

Flash point: no data

Explosive Limits: LEL: No data UEL: No data

Fire Fighting Instructions: As in any fire, wear self-contained breathing apparatus pressure demand

(MSHA/NIOSH approved or equivalent), and full protective gear to prevent contact

with skin and eyes.

Flammable Properties and Hazards: no data available

Extinguishing Media: Use alcohol-resistant foam, carbon dioxide, water, or dry chemical spray when

fighting fires involving this material.

**Unsuitable Media:** no data available.

#### 6: Accidental release measures

7: Handling and storage

**Label Information** 

If materials are released or spilled: Wear a NIOSH/MSHA approved self-contained breathing apparatus and appropriate

personal protection equipment (rubber boots, safety goggles, heavy rubber gloves). Vacuum or sweep up material and place in disposal container. Avoid raising dust. After

removal, ventilate contaminated area and flush thoroughly with water.

**Hazard Label Information:**Avoid contact with skin and eyes. Do not reuse container. Use with adequate ventilation. **Precautions to be taken in handling:**Avoid breathing in dust, vapour, mist, gas. Avoid contact with eyes, skin, and clothing.

Avoid breathing in dust, vapour, mist, gas. Avoid contact with eyes, skin, and clothing. Avoid prolonged or repeated exposure. Do not reuse the container. Use with adequate

ventilation. Wash thoroughly after handling.

Precautions to be taken in Storing: Store at the correct temperature.

#### 8: Exposure Control / Personal Protection

Protective equipment summary – Hazard Eye wash station in work area. Lab coat. Latex disposable gloves. Safety glasses.

Safety shower in work area. Vent hood.

Respiratory Equipment (Specific type):

Eye Protection:

Protective gloves:

No data available.

Safety glasses.

Latex disposable gloves.

Other Protective Clothing: Laboratory coat.

Engineering Controls (Ventillation etc)

Use process enclosures, local exhaust ventilation, or other engineering controls to control

airborne levels below recommended exposure limits.

Work/Hygenic/Maintenance Practices: DO NOT take internally. Facilities storing or utilizing this material should be equipped with

No data.



### 9: Physical and Chemical Properties

Vapour density (vs Air = 1): No data. **Physical States:** [ ] Gas [ ] Liquid [ X] Solid Evaporation rate (vs butyl acetate = 1)No data. Melting point: No data.

Solubility in water: soluble to 10mg/ml Boiling point: No data Percent volatile: No data. Auto ignition point: No data Corrosive Rate: No data. Flash point: No data. Method:

**Explosive Limits:** LEL: No data UEL: No data. A lyophilised powder. Appearance and odour: Specific gravity (water = 1) No data. No odour.

:Ha

Vapour pressure (vs Air or mm Hg) No data.

10: Stability and reactivity

Stability: ] Unstable [ X] Stable

No data available. Conditions to avoid: Material incompatibility: No data available

Hazardous decomposition/ byproducts: No data

[ ] Will occur [ X] Will not occur Hazardous polymerisation:

Conditions to avoid: No data available

11: Toxicological Information

**Toxicological Information:** The toxicological effects of this compound have not been thoroughly studied.

Carcinogenic/Other Information: No data available

Carcinogenicity: NTP? No IARC Monographs? No OSHA Regulated? No

12: Ecological Information: Runoff from fire control or dilution water may cause pollution.

13: Waste Disposal Method: Dispose in accordance with local, state and federal regulations

14. Transport Information

Land Transport (US DOT)

**DOT Proper Shipping Name:** No data available.

**Additional Transport Information:** Transport in accordance with local, state and federal regulations.

#### 15. Regulatory Information

# **US EPA SARA Title III**

Ryanodine receptor 2 (RYR2) (dephoSer2808) pAb serum	CAS#	Sec.302 (EHS)	Sec.304 RQ	Sec.313 (TRI)	Sec.110
	NA	No	No	No	No
USA EPA CAA, CWA, TSCA Hazardous Components (Chemical name) Ryanodine receptor 2 (RYR2) (dephoSer2808) pAb serum	CAS#	EPA CAA	EPA CWA NPDES	EPA TSCA	CA PROP 65
	NA	No	No	No	No

## 16 Other Information

#### **COMPANY POLICY or DISCLAIMER**

For research use only, not for human or veterinary clinical use.

DISCLAIMER: This information is believed to be accurate and full and represents the best information currently available to us. However, we make no warranty of merchantability or any other warrant, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular